Mylan N.V. (MYL)
| Market Cap | 8.59B |
| Revenue (ttm) | 11.51B |
| Net Income (ttm) | 266.40M |
| Shares Out | 516.90M |
| EPS (ttm) | 0.52 |
| PE Ratio | 30.74 |
| Forward PE | 3.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Nov 16, 2021 |
| Last Price | $15.86 |
| Previous Close | $15.86 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 15.34 - 16.15 |
| Day's Volume | 0 |
| 52-Week Range | 12.75 - 23.11 |
News
The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.
Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.
Mylan (MYL) delivered earnings and revenue surprises of 14.78% and -0.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.
Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a...
HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepte...
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
To enhance the effectiveness of screening for value stocks, one method is to consider stocks whose "Graham blended multiplier" is less than 22.5. Developed by Benjamin Graham, the father of va...
In this article you are going to find out whether hedge funds think Mylan N.V. (NASDAQ:MYL) is a good investment right now. We like to check what the smart money thinks first before doing exte...
Going by the historical performance, we believe that the stock price of Mylan, a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current lev...
Two traders sift through a group of stocks "on sale" to find bargain buys in the market.
The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.
HERTFORDSHIRE, England and PITTSBURGH, Sept. 15, 2020 /PRNewswire/ -- Mylan N.V.
Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.
HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
Mylan N.V. MYL, +2.26% said Tuesday it will pay EUR641.9 million ($756.8 million) for Aspen Pharmacare Holdings Ltd.
HERTFORDSHIRE, England, and PITTSBURGH, Sept. 8, 2020 /PRNewswire/ -- Mylan N.V.
Mylan (MYL) reported earnings 30 days ago. What's next for the stock?
It might seem odd on Main Street that the S&P 500 has managed to recapture all its losses after the panic selling seen in February and March.
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Aug. 31, 2020 /PRNewswire/ -- Mylan N.V.
HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2020 /PRNewswire/ -- Mylan N.V.
Los Angeles, California--(Newsfile Corp. - August 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan ...
Los Angeles, California--(Newsfile Corp. - August 24, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan ...
Los Angeles, California--(Newsfile Corp. - August 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.
Los Angeles, California--(Newsfile Corp. - August 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.
Los Angeles, California--(Newsfile Corp. - August 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.
HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ -- Mylan N.V.
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V.
Goodwill and intangibles form $20.48 billion of Mylan’s $30.16 billion balance sheet. The company owes about $12 billion in long-term debt.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclus...
Mylan, Inc. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript
Mylan N.V. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
Generic Drugs And Tensions With China: The Case For Mylan
Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Mylan N.V. MYL, +3.55% said Thursday it had net income of $39.4 million, or 8 cents a share, in the second quarter, after a loss of $168.5 million, or 33 cents a share, in the year-earlier per...
Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.
HERTFORDSHIRE, England and PITTSBURGH, Aug. 6, 2020 /PRNewswire/ -- Mylan N.V.
Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HERTFORDSHIRE, England and PITTSBURGH, July 22, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financi...
NEW YORK, July 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7,...
Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug ...
HERTFORDSHIRE, England and PITTSBURGH, July 7, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nati...
About MYL
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the... [Read more...]
| Industry Drug Manufacturers—Specialty & Generic | Founded 1961 |
| CEO Heather M. Bresch | Employees 35,000 |
| Stock Exchange NASDAQ | Ticker Symbol MYL |
Financial Performance
In 2019, Mylan's revenue was $11.50 billion, an increase of 0.58% compared to the previous year's $11.43 billion. Earnings were $16.80 million, a decrease of -95.23%.